Boyu Capital is a private equity firm that invests in consumer, retail, media and technology, healthcare, and financial services sectors.
Business Model: B2C
Revenue: $5M
Employees: 11-50
Address: 88 Queensway
City: Hong Kong
State: other
Zip:
Country: HK
Boyu Capital Consultancy Co. Ltd is a private equity firm specializing in investments in China. Boyu Capital Consultancy Co. Ltd was founded on September 28, 2010 and is based in Hong Kong with an additional office in Beijing, China.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
9/2017 | LifeMine Therapeutics | Series A | 0 |
6/2021 | RecBio | Series C | 156.3M |
5/2018 | Brii Biosciences | Venture Round | 260M |
9/2019 | Chengjia Apartment | Series A | 300M |
12/2020 | SciNeuro | Series A | 100M |
11/2017 | Berry Oncology | Series A | 121.2M |
5/2013 | Berry Genomics | Series B | 14.7M |
5/2018 | China Chengxin Credit | Series A | 0 |
10/2021 | WT Microtech Medical | Series E | 153M |
4/2021 | J&a;T Express | Private Equity Round | 2B |
8/2021 | MediTrust Health | Series C | 0 |
8/2021 | Abogen Biosciences | Series C | 0 |
3/2020 | Yatsen Holding | Series D | 240M |
6/2022 | Frontera Therapeutics | Series B | 0 |
1/2019 | Antengene Corporation | Series B | 0 |
1/2019 | Yimidida | Series D | 266.1M |
3/2020 | Yuanfudao | Series G | 1B |
3/2020 | Pinduoduo | Post-IPO Equity | 1.1B |
6/2019 | Waterdrop | Series C | 144.6M |
4/2021 | Adcentrx Therapeutics | Series A | 50M |
9/2022 | Animoca Brands | Convertible Note | 110M |
9/2012 | Alibaba Group | Private Equity Round | 0 |
5/2018 | CStone Pharmaceuticals | Series B | 260M |
11/2021 | Positive Sequence Biology | Series A | 0 |
1/2021 | 4Paradigm | Series D | 0 |
11/2021 | Edge Medical Robotics | Series C | 0 |
1/2021 | Lalamove | Series F | 1.5B |
6/2021 | ArriVent Biopharma | Series A | 81M |
2/2022 | ArriVent Biopharma | Series A | 69M |
11/2020 | D3 Bio | Series A | 200M |
6/2014 | COFCO | Post-IPO Equity | - |
12/2022 | ArriVent Biopharma | Series B | 0 |
6/2022 | Evat Master | Series A | 0 |
2/2014 | LY.com | Series C | 82.3M |
12/2021 | Jinke | Post-IPO Equity | 478.6M |
8/2018 | KLOOK | Series D | 200M |
7/2020 | Antengene Corporation | Series C | 97M |
12/2021 | Recurrent.ai | Venture Round | 38M |
7/2016 | CStone Pharmaceuticals | Series A | 150M |
11/2018 | NetEase Cloud Music | Series B | 600M |
8/2021 | MediTrust Health | Series C | 308.3M |
12/2019 | Kuaishou Technology | Series F | 3B |
7/2018 | Trax | Series D | 0 |
2/2018 | Viela Bio | Series A | 0 |
11/2021 | J&a;T Express | Private Equity Round | 0 |
11/2021 | Vision Medicals | Series D | 47M |
7/2018 | Curon Biopharma | Series A | 150M |
8/2021 | Zeekr | Series A | 500M |
7/2018 | MEGVII | Series D | - |
8/2020 | Yuanfudao | Series G | 1.2B |
2/2017 | iQiyi | Series G | 1.5B |
8/2021 | Pulse Medical Technology | Series C | 0 |
9/2021 | XSKY Data Technology | Series E | 0 |
9/2018 | LianLian Pay | Venture Round | 146.6M |
5/2022 | Shuaike Pet Food Products | Private Equity Round | 0 |
3/2022 | MoreSec | Series D | 0 |
1/2021 | KLOOK | Series E | 0 |
6/2022 | Frontera Therapeutics | Series B | 0 |
6/2022 | Evat Master | Series A | 0 |
5/2022 | Shuaike Pet Food Products | Private Equity Round | 0 |
3/2022 | MoreSec | Series D | 0 |
2/2022 | ArriVent Biopharma | Series A | 0 |
12/2021 | Recurrent.ai | Venture Round | 0 |
12/2021 | Jinke | Post-IPO Equity | 0 |
11/2021 | Vision Medicals | Series D | 0 |
11/2021 | J&a;T Express | Private Equity Round | 0 |
11/2021 | Positive Sequence Biology | Series A | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|